Header cover image

South Korean (KOSPI) Biotech Industry Analysis

UpdatedJan 31, 2025
DataAggregated Company Financials
Companies117
  • 7D1.4%
  • 3M0.3%
  • 1Y28.1%
  • YTD3.2%

The Biotech industry is up 1.4% in the last week, with ALTEOGEN up 4.3%. This means that the industry has gained 28% over the past year. As for the next few years, earnings are expected to grow by 85% per annum.

Industry Valuation and Performance

Has the South Korean Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 01 Feb 2025₩93.8t₩10.5t-₩1,004,347,149,181.0023.1x-93.4x9x
Mon, 30 Dec 2024₩90.8t₩10.5t-₩1,004,347,149,181.0024.5x-90.4x8.7x
Wed, 27 Nov 2024₩86.2t₩10.5t-₩927,369,993,128.0022.8x-92.9x8.2x
Fri, 25 Oct 2024₩97.0t₩10.3t-₩653,791,712,887.0027.1x-148.3x9.4x
Sun, 22 Sep 2024₩97.6t₩10.3t-₩663,381,294,267.0025.5x-147.1x9.4x
Tue, 20 Aug 2024₩94.8t₩9.9t-₩648,577,713,618.0028.5x-146.2x9.6x
Thu, 18 Jul 2024₩88.7t₩9.9t-₩651,620,427,048.0023.2x-136.1x9x
Sat, 15 Jun 2024₩83.7t₩9.9t-₩635,976,480,448.0022x-131.7x8.5x
Mon, 13 May 2024₩82.3t₩9.6t-₩568,051,080,968.0023.6x-144.8x8.6x
Wed, 10 Apr 2024₩79.9t₩9.6t-₩665,568,465,312.0021.1x-120x8.3x
Fri, 08 Mar 2024₩79.3t₩9.7t-₩529,895,238,747.0056.5x-149.6x8.1x
Sun, 04 Feb 2024₩74.6t₩9.7t-₩537,261,689,777.0064.1x-138.9x7.7x
Tue, 02 Jan 2024₩67.9t₩10.1t-₩324,278,048,367.0029.3x-209.3x6.7x
Thu, 30 Nov 2023₩58.1t₩10.1t-₩322,067,111,699.0025.6x-180.5x5.8x
Sat, 28 Oct 2023₩52.6t₩10.2t-₩239,053,318,689.0027.6x-219.9x5.2x
Mon, 25 Sep 2023₩55.7t₩10.2t-₩239,053,318,689.0028.8x-233.1x5.5x
Wed, 23 Aug 2023₩57.2t₩10.2t-₩195,129,377,099.0037.8x-293.2x5.6x
Fri, 21 Jul 2023₩56.9t₩10.3t-₩151,534,704,579.0026.4x-375.4x5.5x
Sun, 18 Jun 2023₩60.8t₩10.3t-₩151,534,704,579.0029.8x-401.1x5.9x
Tue, 16 May 2023₩61.2t₩11.0t₩317.8b25.6x192.5x5.6x
Thu, 13 Apr 2023₩65.1t₩11.0t₩318.9b24.6x204x5.9x
Sat, 11 Mar 2023₩57.5t₩11.3t₩964.8b24.8x59.7x5.1x
Mon, 06 Feb 2023₩61.6t₩11.3t₩970.8b25x63.5x5.4x
Wed, 04 Jan 2023₩57.7t₩11.4t₩685.0b22.6x84.2x5.1x
Fri, 02 Dec 2022₩61.3t₩10.8t₩237.0b22.3x258.4x5.6x
Sun, 30 Oct 2022₩59.7t₩10.8t₩348.0b19.1x171.4x5.5x
Tue, 27 Sep 2022₩55.7t₩10.8t₩391.5b19.8x142.2x5.1x
Thu, 25 Aug 2022₩69.2t₩10.9t₩644.2b24.7x107.4x6.4x
Sat, 23 Jul 2022₩70.5t₩10.7t₩597.6b26.6x117.9x6.6x
Mon, 20 Jun 2022₩61.4t₩10.6t₩627.1b23.4x97.9x5.8x
Wed, 18 May 2022₩64.5t₩10.0t₩870.7b26.1x74x6.5x
Fri, 15 Apr 2022₩71.6t₩10.0t₩898.1b27.6x79.7x7.2x
Sun, 13 Mar 2022₩75.1t₩9.4t₩747.3b34.8x100.5x8x
Tue, 08 Feb 2022₩74.9t₩9.4t₩787.4b33.6x95.1x8x
Price to Earnings Ratio

95.1x


Total Market Cap: ₩74.9tTotal Earnings: ₩787.4bTotal Revenue: ₩9.4tTotal Market Cap vs Earnings and Revenue0%0%0%
South Korean Biotech Industry Price to Earnings3Y Average -46.9x202320242025
Current Industry PE
  • Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 9.0x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have grown 3.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the South Korean Healthcare industry?

KR Market0.80%
Healthcare1.53%
Biotech1.39%
Biotech1.39%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A196170 ALTEOGEN₩371.50k2.6%
+₩506.3b
386.3%PS266.2x
A310210 Voronoi₩86.10k7.2%
+₩104.1b
155.5%PB20.7x
A145020 Hugel₩237.50k2.8%
+₩71.6b
45.0%PE23.3x
A298380 ABL Bio₩36.35k3.0%
+₩50.7b
62.3%PS54.3x
A226950 OliX Pharmaceuticals₩16.30k15.4%
+₩40.2b
17.0%PS18.6x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

A005690

₩7,980.00

Pharmicell

7D

-13.0%

1Y

37.6%

A068270

₩179,700.00

Celltrion

7D

-0.3%

1Y

2.5%

A228760

₩18,210.00

Genomictree

7D

-5.6%

1Y

2.8%

A950160

₩28,700.00

Kolon TissueGene

7D

-1.5%

1Y

133.5%

A140610

₩27,050.00

Ensol Biosciences

7D

14.9%

1Y

738.8%

A347850

₩58,000.00

D&D Pharmatech

7D

4.5%

1Y

n/a

A196170

₩371,500.00

ALTEOGEN

7D

2.6%

1Y

386.3%